---
layout: default
title: Zinc Acetate
parent: Model Prediction Only (L5)
nav_order: 895
evidence_level: L5
indication_count: 10
---

# Zinc Acetate
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Zinc Acetate: From an Unspecified Original Indication to Severe Nonproliferative Diabetic Retinopathy

## One-Sentence Summary

> Zinc acetate (DrugBank ID: DB14487) has no original indication or mechanism-of-action data recorded in this evidence pack.
> The TxGNN model predicts it may be effective for **severe nonproliferative diabetic retinopathy**,
> but this prediction is currently supported by **no clinical trials and no published literature** — it rests on model score alone.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not specified in available data |
| Predicted New Indication | Severe Nonproliferative Diabetic Retinopathy |
| TxGNN Prediction Score | 99.97% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| India Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism-of-action data for zinc acetate is not available in this evidence pack, and no original approved indication is recorded either. Based on general pharmacological knowledge of zinc, zinc ions act as a cofactor for Cu/Zn superoxide dismutase (SOD), an antioxidant enzyme. This has led to a theoretical hypothesis that zinc supplementation could help mitigate the oxidative-stress pathways implicated in diabetic retinopathy.

However, this connection is a mechanistic extrapolation, not an evidence-based finding — there is no clinical trial, preclinical study, or published literature in this evidence pack that directly links zinc acetate to diabetic retinopathy or its complications. The TxGNN score of 99.97% reflects the strength of an association within the model's knowledge graph, not confirmed clinical or biological evidence. Without an established original indication for zinc acetate to anchor a comparison, the biological plausibility of this specific repurposing signal cannot currently be assessed with confidence.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## India Market Information

Zinc acetate currently has **no registered market authorizations in India** based on the available data (market status: Not Marketed; total registrations: 0).

---

## Safety Considerations

**Drug Interactions**: A drug-drug interaction (DDI) query returned 100 total interactions for zinc acetate (source: DDInter). Most are classified as Minor severity, but the following interacting agents are flagged as **Moderate**:

| Interacting Drug | Level |
|---|---|
| Alendronic acid | Moderate |
| Risedronic acid | Moderate |
| Ibandronate | Moderate |
| Tetracycline | Moderate |
| Baloxavir marboxil | Moderate |

Specific interaction mechanisms are not detailed in this evidence pack; a full DDI review (all 100 entries) is recommended before clinical use is considered.

No package insert warnings or contraindications are currently available in this evidence pack — please refer to the drug's official labeling once available (see Data Gap DG001 below).

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The predicted indication (severe nonproliferative diabetic retinopathy) has zero supporting clinical trials or literature — evidence level L5, the lowest tier, meaning the signal is model-generated only. In addition, a **Blocking** data gap (DG001: TFDA/label warnings and contraindications unavailable) prevents this candidate from even entering a preliminary safety review (S1).

**To proceed, the following is needed:**
- Resolve DG001 (Blocking): obtain official package insert / label warnings and contraindications
- Resolve DG002 (High): obtain confirmed mechanism of action from DrugBank or another authoritative source
- Establish zinc acetate's actual original/approved indication, to allow a genuine mechanistic and clinical comparison
- Generate or locate preclinical or clinical evidence specifically evaluating zinc (or zinc acetate) in diabetic retinopathy
- Note: among other TxGNN candidates for this drug, **bronchitis** (rank 2, L4, decision stage S1, "Research Question") has at least one completed clinical trial (NCT03309995, zinc lozenges in the common cold) and may warrant separate evaluation as a comparatively stronger-evidence candidate
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

